Patents by Inventor Christina A. Scherer
Christina A. Scherer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11325913Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.Type: GrantFiled: June 29, 2020Date of Patent: May 10, 2022Assignee: THE BROAD INSTITUTE, INC.Inventors: Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
-
Publication number: 20200399276Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.Type: ApplicationFiled: June 29, 2020Publication date: December 24, 2020Applicant: THE BROAD INSTITUTE, INC.Inventors: EAMON COMER, NOBUTAKA KATO, CHRISTINA SCHERER, JESSICA BASTIEN, JEREMY DUVALL, TIMOTHY LEWIS, MORGANE SAYES, MATTHEW LEIGHTY, JUN PU, JENNIFER BEAUDOIN, BERTRAND BRAIBANT, BENITO MUNOZ
-
Patent number: 10738055Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.Type: GrantFiled: July 23, 2018Date of Patent: August 11, 2020Assignee: The Broad Institute, Inc.Inventors: Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
-
Publication number: 20190055252Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.Type: ApplicationFiled: July 23, 2018Publication date: February 21, 2019Applicant: THE BROAD INSTITUTE, INC.Inventors: EAMON COMER, NOBUTAKA KATO, CHRISTINA SCHERER, JESSICA BASTIEN, JEREMY DUVALL, TIMOTHY LEWIS, MORGANE SAYES, MATTHEW LEIGHTY, JUN PU, JENNIFER BEAUDOIN, BERTRAND BRAIBANT, BENITO MUNOZ
-
Patent number: 10059711Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.Type: GrantFiled: November 11, 2014Date of Patent: August 28, 2018Assignee: The Broad Institute, Inc.Inventors: Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
-
Publication number: 20160289235Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.Type: ApplicationFiled: November 11, 2014Publication date: October 6, 2016Applicant: THE BROAD INSTITUTE, INC.Inventors: EAMON COMER, NOBUTAKA KATO, CHRISTINA SCHERER, JESSICA BASTIEN, JEREMY DUVALL, TIMOTHY LEWIS, MORGANE SAYES, MATTHEW LEIGHTY, JUN PU, JENNIFER BEAUDOIN, BERTRAND BRAIBANT, BENITO MUNOZ
-
Patent number: 9428507Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.Type: GrantFiled: June 20, 2014Date of Patent: August 30, 2016Assignees: The Broad Institute, Inc., President and Fellows of Harvard CollegeInventors: Eamon Comer, Benito Munoz, Jennifer A. Beaudoin, Sebastian T. Le Quement, Christina Scherer, Jeremy Duvall, Nobutaka Kato, Micah Maetani, Bertrand Braibant
-
Publication number: 20160152617Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.Type: ApplicationFiled: June 20, 2014Publication date: June 2, 2016Inventors: Eamon COMER, Benito MUNOZ, Jennifer A. BEAUDOIN, Sebastian T. LE QUEMENT, Christina SCHERER, Jeremy DUVALL, Nobutaka KATO, Micah MAETANI, Bertrand BRAIBANT
-
Patent number: 9163222Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: GrantFiled: November 14, 2012Date of Patent: October 20, 2015Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, P Campion Fellin, Christina A Scherer, Tory Hagen, Amy Olson
-
Patent number: 9090947Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: GrantFiled: May 28, 2013Date of Patent: July 28, 2015Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
-
Patent number: 8951768Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: GrantFiled: July 11, 2011Date of Patent: February 10, 2015Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, P. Campion Fellin, Christina A. Scherer, Tory Hagen, Amy Olson
-
Patent number: 8883477Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: June 14, 2013Date of Patent: November 11, 2014Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 8859251Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: July 1, 2013Date of Patent: October 14, 2014Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20140037717Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: September 5, 2013Publication date: February 6, 2014Applicant: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
-
Publication number: 20140010800Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: May 28, 2013Publication date: January 9, 2014Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
-
Publication number: 20140005101Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: June 14, 2013Publication date: January 2, 2014Applicant: Kineta Two LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20140005102Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: July 1, 2013Publication date: January 2, 2014Applicant: Kineta Two LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 8551772Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: GrantFiled: November 22, 2011Date of Patent: October 8, 2013Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
-
Patent number: 8486678Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: February 1, 2012Date of Patent: July 16, 2013Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20120321608Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: May 10, 2012Publication date: December 20, 2012Applicant: Kineta Two, LLCInventors: SHAWN P. IADONATO, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux